文献速递创伤与烧伤重症综合管理与镇静镇痛

血浆检测区分创伤性凝血病中的纤溶亢进与纤溶关闭亚组

Plasma-based assays distinguish hyperfibrinolysis and shutdown subgroups in trauma-induced coagulopathy.
PubMed 文献 · J Trauma Acute Care Surg · 2022-06-10
一句话结论在创伤性凝血病中,纤溶亢进与纤溶关闭亚组在血浆凝血酶生成、纤维蛋白形成与结构上存在差异,但tPA触发的纤溶酶生成能力相似。

本研究为观察性横断面创伤队列,用全血血栓弹力图定义纤溶关闭(LY30<0.9%,n=11)和纤溶亢进(LY30>3%,n=9),并取非损伤对照。用荧光、共聚焦显微镜、浊度法和荧光校准纤溶酶测定法检测血小板贫乏血浆的凝血酶生成、纤维蛋白结构和形成、纤溶酶生成。结果显示两亚组均有自发性凝血酶生成,纤溶亢进滞后时间更短;纤溶亢进纤维蛋白网络更致密;无tPA时纤溶关闭纤维蛋白形成速率更快,纤溶亢进血凝块自发性溶解;tPA刺激的纤溶酶生成两组相似。LY30、纤维蛋白结构和溶解差异与pH相关。

要点

  • 全血血栓弹力图定义:纤溶关闭LY30<0.9%(n=11),纤溶亢进LY30>3%(n=9),对照组为非损伤者。
  • 纤溶亢进与纤溶关闭患者血小板贫乏血浆均出现自发性凝血酶生成,对照组未检测到。
  • 纤溶亢进血浆凝血酶生成滞后时间短于纤溶关闭;加入组织因子后该差异被掩盖,但纤溶亢进凝血酶生成增加。
  • 纤溶亢进血浆纤维蛋白网络较纤溶关闭更致密;无tPA时纤溶关闭纤维蛋白形成速率更快,纤溶亢进血凝块自发性溶解。
  • tPA刺激的纤溶酶生成在纤溶亢进与纤溶关闭间相似;LY30、纤维蛋白结构和溶解差异与pH相关。

适用人群与场景

  • 观察性横断面创伤队列中,经全血血栓弹力图定义纤溶关闭(LY30<0.9%,n=11)或纤溶亢进(LY30>3%,n=9)的创伤患者。
  • 非损伤对照者提供比较样本。

诊断标准与关键阈值

  • 纤溶关闭:全血血栓弹力图LY30(30分钟溶解百分比)<0.9%。
  • 纤溶亢进:全血血栓弹力图LY30>3%。

研究设计与关键结果

  • 研究类型:观察性横断面创伤队列,样本量纤溶关闭n=11、纤溶亢进n=9,另设非损伤对照。
  • 对照组血小板贫乏血浆未检测到自发性凝血酶生成;纤溶亢进与纤溶关闭患者血小板贫乏血浆均出现自发性凝血酶生成,且纤溶亢进滞后时间短于纤溶关闭。
  • 加入组织因子后上述滞后时间差异被掩盖,但纤溶亢进样本凝血酶生成增加。
  • 纤溶亢进血小板贫乏血浆形成的纤维蛋白网络较纤溶关闭更致密。
  • 无tPA时,纤溶关闭纤维蛋白形成速率快于纤溶亢进,但纤溶亢进血凝块发生自发性溶解;加入tPA后这些差异被掩盖。
  • tPA刺激的纤溶酶生成在纤溶亢进与纤溶关闭样本间相似。
  • LY30、纤维蛋白结构和溶解的差异与pH相关。

证据类型、等级与局限

  • 证据类型:观察性横断面研究;证据等级:预后/流行病学,Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在血小板贫乏血浆中表征这些活性有助于开展研究,以识别促进创伤不良结局的机制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Trauma patients with abnormal fibrinolysis have increased morbidity and mortality. Knowledge of mechanisms differentiating fibrinolytic phenotypes is important to optimize treatment. We hypothesized that subjects with abnormal fibrinolysis identified by whole blood viscoelastometry can also be distinguished by plasma thrombin generation, clot structure, fibrin formation, and plasmin generation measurements.

METHODS: Platelet-poor plasma (PPP) from an observational cross-sectional trauma cohort with fibrinolysis shutdown (% lysis at 30 minutes [LY30] < 0.9, n = 11) or hyperfibrinolysis (LY30 > 3%, n = 9) defined by whole blood thromboelastography were studied. Noninjured control subjects provided comparative samples. Thrombin generation, fibrin structure and formation, and plasmin generation were measured by fluorescence, confocal microscopy, turbidity, and a fluorescence-calibrated plasmin assay, respectively, in the absence/presence of tissue factor or tissue plasminogen activator (tPA).

RESULTS: Whereas spontaneous thrombin generation was not detected in PPP from control subjects, PPP from hyperfibrinolysis or shutdown patients demonstrated spontaneous thrombin generation, and the lag time was shorter in hyperfibrinolysis versus shutdown. Addition of tissue factor masked this difference but revealed increased thrombin generation in hyperfibrinolysis samples. Compared with shutdown, hyperfibrinolysis PPP formed denser fibrin networks. In the absence of tPA, the fibrin formation rate was faster in shutdown than hyperfibrinolysis, but hyperfibrinolysis clots lysed spontaneously; these differences were masked by addition of tPA. Tissue plasminogen activator-stimulated plasmin generation was similar in hyperfibrinolysis and shutdown samples. Differences in LY30, fibrin structure, and lysis correlated with pH.

CONCLUSION: This exploratory study using PPP-based assays identified differences in thrombin generation, fibrin formation and structure, and lysis in hyperfibrinolysis and shutdown subgroups. These groups did not differ in their ability to promote tPA-triggered plasmin generation. The ability to characterize these activities in PPP facilitates studies to identify mechanisms that promote adverse outcomes in trauma.

LEVEL OF EVIDENCE: Prognostic/Epidemiological; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Lawson MA, Holle LA, Dow NE, et al. Plasma-based assays distinguish hyperfibrinolysis and shutdown subgroups in trauma-induced coagulopathy. J Trauma Acute Care Surg. 2022. PMID: 35687811. doi:10.1097/TA.0000000000003723

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。